<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096782</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0051</org_study_id>
    <secondary_id>NCI-2018-01236</secondary_id>
    <secondary_id>2016-0051</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT03096782</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma</brief_title>
  <official_title>Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well an umbilical cord blood transplant with added sugar
      works with chemotherapy and radiation therapy in treating patients with leukemia or lymphoma.
      Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant
      helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem
      cells) and cancer cells. When the healthy stem cells from a donor are infused into the
      patient they may help the patient's bone marrow make stem cells, red blood cells, white blood
      cells, and platelets. The umbilical cord blood cells will be grown (&quot;expanded&quot;) on a special
      layer of cells collected from the bone marrow of healthy volunteers in a laboratory. A type
      of sugar will also be added to the cells in the laboratory that may help the transplant to
      &quot;take&quot; faster.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the safety and feasibility of transplantation of cord blood which is expanded
      in mesenchymal precursor cell (MPC) co-cultures then fucosylated with fucosyltransferase
      (FT)-VI and guanosine diphosphate (GDP) fucose prior to infusion in patients with hematologic
      malignancies following high-dose therapy.

      II. To evaluate the time to engraftment using expanded fucosylated cord blood.

      SECONDARY OBJECTIVES:

      I. To evaluate the rate and severity of graft versus host disease. II. To evaluate the rates
      of infectious complications. III. To evaluate the rates of disease-free and overall survival.

      OUTLINE: Patients are assigned to 1 of 3 groups.

      GROUP I: Patients receive rituximab intravenously (IV) on day -11, anti-thymocyte globulin
      (ATG) IV over 4 hours on days -9 and -8, fludarabine IV over 1 hour, clofarabine IV over 1
      hour, busulfan IV over 3 hours on days -7 through -4, and total body irradiation (TBI) on day
      -3. Patients then receive a cord blood transfusion IV on day 0.

      GROUP II: Patients receive ATG IV over 4 hours on days -8 and -7, fludarabine IV over 30
      minutes on days -5 to -2, and melphalan IV over 30 minutes on day -2. Patients then receive a
      cord blood transplant IV on day 0.

      GROUP III: Patients receive ATG IV over 4 hours on days -8 and -7, fludarabine IV over 30
      minutes on days -6 to -3, cyclophosphamide IV over 1 hour on day -6, and one low-dose
      treatment of TBI on day -1. Patients then receive a cord blood transplant IV on day 0.

      GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or orally
      (PO) twice daily (BID) on days -3 with a taper beginning on day 100 in the absence of GVHD,
      tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and
      filgrastim-sndz subcutaneously (SC) once daily (QD) starting on day 0 until white blood count
      begins to recover.

      After completion of study treatment, patients are followed up at months 1, 3, 6, and 12.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of cord blood infusion</measure>
    <time_frame>At 12 months after transplant</time_frame>
    <description>Will be defined by sterile expanded mesenchymal stem cell (MSC) product. Feasibility is defined as having a sterile expanded MSC product which was &gt; 50% fucosylated in the majority of the patients enrolled.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to engraftment</measure>
    <time_frame>Up to 12 months after transplant</time_frame>
    <description>The distribution of time to engraftment will be estimated using Kaplan-Meier plots and the relationship to covariates evaluated by piecewise exponential Bayesian regression. Time to engraftment will be monitored by the Bayesian statistical method of Thall et al., assuming an accrual rate of 10 patients per year with a maximum sample size of 25 patients. A mean time to engraftment (TTE) of 7 days will be considered desirable and a mean TTE of 21 days will be considered undesirable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Up to12 months</time_frame>
    <description>The distribution of disease-free survival time will be estimated using Kaplan-Meier plots and their relationships to covariates evaluated by piecewise exponential Bayesian regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 12 months after transplant</time_frame>
    <description>The distribution of disease-free survival time will be estimated using Kaplan-Meier plots and their relationships to covariates evaluated by piecewise exponential Bayesian regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality (TRM)</measure>
    <time_frame>Up to 12 months after transplant</time_frame>
    <description>TRM will be evaluated by tabulation, Kaplan-Meier plots, and piecewise exponential Bayesian regression.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome</condition>
  <condition>Chemotherapy-Related Leukemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Langerhans Cell Histiocytosis</condition>
  <condition>Minimal Residual Disease</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelodysplastic Syndrome With Excess Blasts</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Hodgkin Lymphoma</condition>
  <condition>Refractory Acute Lymphoblastic Leukemia</condition>
  <condition>Refractory Myelodysplastic Syndrome</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Therapy-Related Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Group I (chemotherapy, TBI, cord blood)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab IV on day -11, ATG IV over 4 hours on days -9 and -8, fludarabine IV over 1 hour, clofarabine IV over 1 hour, busulfan IV over 3 hours on days -7 through -4, and TBI on day -3. Patients then receive a cord blood transfusion IV on day 0.
GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (chemotherapy, cord blood)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ATG IV over 4 hours on days -8 and -7, fludarabine IV over 30 minutes on days -5 to -2, and melphalan IV over 30 minutes on day -2. Patients then receive a cord blood transplant IV on day 0.
GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III (chemotherapy, TBI, cord blood)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ATG IV over 4 hours on days -8 and -7, fludarabine IV over 30 minutes on days -6 to -3, cyclophosphamide IV over 1 hour on day -6, and one low-dose treatment of TBI on day -1. Patients then receive a cord blood transplant IV on day 0.
GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (chemotherapy, TBI, cord blood)</arm_group_label>
    <arm_group_label>Group II (chemotherapy, cord blood)</arm_group_label>
    <arm_group_label>Group III (chemotherapy, TBI, cord blood)</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>ATS</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (chemotherapy, TBI, cord blood)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (chemotherapy, TBI, cord blood)</arm_group_label>
    <other_name>Clofarex</other_name>
    <other_name>Clolar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group III (chemotherapy, TBI, cord blood)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim-sndz</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Group I (chemotherapy, TBI, cord blood)</arm_group_label>
    <arm_group_label>Group II (chemotherapy, cord blood)</arm_group_label>
    <arm_group_label>Group III (chemotherapy, TBI, cord blood)</arm_group_label>
    <other_name>Filgrastim Biosimilar Filgrastim-sndz</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (chemotherapy, TBI, cord blood)</arm_group_label>
    <arm_group_label>Group II (chemotherapy, cord blood)</arm_group_label>
    <arm_group_label>Group III (chemotherapy, TBI, cord blood)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group II (chemotherapy, cord blood)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine nitrogen mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Group I (chemotherapy, TBI, cord blood)</arm_group_label>
    <arm_group_label>Group II (chemotherapy, cord blood)</arm_group_label>
    <arm_group_label>Group III (chemotherapy, TBI, cord blood)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (chemotherapy, TBI, cord blood)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (chemotherapy, TBI, cord blood)</arm_group_label>
    <arm_group_label>Group II (chemotherapy, cord blood)</arm_group_label>
    <arm_group_label>Group III (chemotherapy, TBI, cord blood)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo total body irradiation</description>
    <arm_group_label>Group I (chemotherapy, TBI, cord blood)</arm_group_label>
    <arm_group_label>Group III (chemotherapy, TBI, cord blood)</arm_group_label>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Umbilical Cord Blood Transplantation</intervention_name>
    <description>Undergo cord blood transplant</description>
    <arm_group_label>Group I (chemotherapy, TBI, cord blood)</arm_group_label>
    <arm_group_label>Group II (chemotherapy, cord blood)</arm_group_label>
    <arm_group_label>Group III (chemotherapy, TBI, cord blood)</arm_group_label>
    <other_name>Cord Blood Transplantation</other_name>
    <other_name>UCB transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have one of the following hematologic malignancies: a. Acute myelogenous
             leukemia (AML), induction failure, high-risk for relapse first remission (with
             intermediate-risk or high-risk cytogenetics, flt3 mutation positive and/or evidence of
             minimal residual disease by flow cytometry), secondary leukemia from prior
             chemotherapy and/or arising from myelodysplastic syndrome (MDS), Langerhan's cell
             histiocytosis, any disease beyond first remission. b. Myelodysplastic syndrome (MDS):
             MDS International Prognostic Scoring System (IPSS) INT-1 will be enrolled only if the
             subjects have failed previous leukemia treatments and are transfusion-dependent. MDS
             may be primary or therapy related, including patients that will be considered for
             transplant. Including the following categories: 1) Revised IPSS intermediate and high
             risk groups, 2) MDS with transfusion dependency, 3) Failure to respond or progression
             of disease on hypomethylating agents, 4) Refractory anemia with excess of blasts, 5)
             Transformation to acute leukemia, 6) Chronic myelomonocytic leukemia, 7) Atypical
             MDS/myeloproliferative syndromes, 8) Complex karyotype, abn(3g), -5/5g-, -7/7g-,
             abn(12p), abn(17p). c. Acute lymphoblastic leukemia (ALL) patients with the following
             will be considered: induction failure, primary refractory to treatment (do not achieve
             complete remission after first course of therapy) or are beyond first remission
             including second or greater remission or active disease. Patients in first remission
             are eligible if they are considered high risk, defined as any of the following
             detected at any time: with translocations 9;22 or 4;11, hypodiploidy, complex
             karyotype, secondary leukemia developing after cytotoxic drug exposure, and/or
             evidence of minimal residual disease, or acute biphenotypic leukemia which excludes &gt;
             7 chromosomal abnormalities, or double hit non-Hodgkin's lymphoma. Non-Hodgkin's
             lymphoma (NHL) in second or third complete remission or relapse (including relapse
             post autologous hematopoietic stem cell transplant), or relapsed double hit lymphoma.
             Small lymphocytic lymphoma (SLL), or chronic lymphocytic leukemia (CLL) with
             progressive disease with progression after standard of care therapy or have
             failed/been intolerant to ibrutinib. Chronic myelogenous leukemia (CML) second chronic
             phase or accelerated phase. Hodgkin's disease (HD): Induction failure after the first
             complete remission, or relapse (including relapse post autologous hematopoietic stem
             cell transplant), or those with active disease.

          -  The first 6 patients must be &gt;= 18 and =&lt; 65 years old. The subsequent patients may
             include pediatric patients &gt;= 12 and =&lt; 65 years old. Eligibility for pediatric
             patients will be determined in conjunction with an MD Anderson Cancer Center (MDACC)
             pediatrician.

          -  Performance score of at least 80% by Karnofsky or performance score (PS) &lt; 3 (Eastern
             Cooperative Oncology Group [ECOG]) (age &gt;= 12 years)

          -  Left ventricular ejection fraction of &gt; 40%.

          -  Pulmonary function test (PFT) demonstrating a diffusion capacity of least 50%
             predicted.

          -  Creatinine =&lt; 1.5 mg/dL for patients 12 years old and older and =&lt; 1 for patients
             younger than 12 years old.

          -  Serum glutamate pyruvate transaminase (SGPT) =&lt; to 2.0 x normal.

          -  Bilirubin =&lt; to 2.0 x normal.

          -  Negative beta human chorionic gonadotropin (HCG) test in a woman with child bearing
             potential defined as not post-menopausal for 12 months or no previous surgical
             sterilization and willing to use an effective contraceptive measure while on study.

          -  Patients must have two cord blood (CB) units available which are matched with the
             patient at 4, 5, or 6/6 HLA class I (serological) and II (molecular) antigens. Each
             cord must contain at least 1.5 x 10^7 total nucleated cells/Kg recipient body weight
             (pre-thaw).

          -  Have identified a backup cells source in case of engraftment failure. The source can
             be autologous, related or unrelated.

          -  Patient must not have a 10/10 HLA matched family member or unrelated donor.

          -  Patients will have a back-up graft from any of the following: an available fraction of
             autologous marrow; or peripheral blood progenitor cells (PBPCs) harvested and
             cryopreserved; or family member donor; or a third cord blood unit.

          -  Prior to initiating chemotherapy in this study, twenty-one or more days must have
             elapsed since the patient's last radiation or chemotherapy administration (Hydrea,
             Gleevec and other tyrosine kinase inhibitors [TKI] as well as intrathecal therapy are
             accepted exceptions).

        Exclusion Criteria:

          -  Patients with known history of human immunodeficiency virus/acquired immunodeficiency
             syndrome (HIV/AIDS).

          -  Patients with positive hepatitis serology that is definitive of active disease.

          -  Active central nervous system (CNS) disease in patient with history of CNS malignancy.

          -  Patients with chronic active hepatitis or cirrhosis. If positive hepatitis serology,
             the study chair may deem the patient eligible based on the results of liver biopsy.

          -  Patients with uncontrolled serious medical condition such as persistent septicemia
             despite adequate antibiotic therapy, decompensated congestive heart failure despite
             cardiac medications or pulmonary insufficiency requiring intubation (excluding primary
             disease for which CB transplantation is proposed), or psychiatric condition that would
             limit informed consent.

          -  Positive beta HCG in female of child-bearing potential defined as not post-menopausal
             for 12 months or no previous surgical sterilization or breast-feeding.

          -  Pediatric patients with acute lymphoblastic leukemia (ALL) that is t (9,22) positive
             in first remission are not eligible unless there is evidence of minimal residual
             disease after initial induction and/or consolidation treatment or the pediatric
             Philadelphia chromosome positive (Ph+) ALL is clinically refractory to available
             therapies with evidence of persistence in the bone marrow or peripheral blood.

          -  Patients with options for treatment that are known to be curative are not eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Olson</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda L. Olson</last_name>
    <phone>713-792-8750</phone>
    <email>alolson@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Olson</last_name>
      <phone>713-792-8750</phone>
    </contact>
    <investigator>
      <last_name>Amanda Olson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Histiocytosis</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

